Newcastle disease virus hemagglutinin neuraminidase as a potential cancer targeting agent

Journal of Cancer

Volumn 7, Issue 4, 2016, Pages 462-466

  Baradaran, Ali ^a   Yusoff, Khatijah ^a   Shafee, Norazizah ^a   Rahim, Raha Abdul ^a  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

Cancer targeting; Hemagglutinin neuraminidase; Lactococcus lactis; Surface display

Indexed keywords

HN PROTEIN; HYBRID PROTEIN;

ANIMAL CELL; ARTICLE; BACTERIAL CELL; BACTERIAL CELL WALL; BREAST CANCER; CHO CELL LINE; DRUG TARGETING; FLUORESCENCE MICROSCOPY; IMMUNOFLUORESCENCE; LACTOBACILLUS PLANTARUM; LACTOCOCCUS LACTIS; NEWCASTLE DISEASE VIRUS; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SURFACE PROPERTY;

EID: 84971571596     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.13566     Document Type: Article

References (25)

1. Fournier P, Schirrmacher V. Oncolytic Newcastle disease virus as cutting edge between tumor and host. Biology. 2013; 2: 936-75.
2. Prestwich RJ, Harrington KJ, Pandha HS, Vile RG, Melcher AA, Errington F. Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Therapy. 2008: 1581-8.
3. Huang Z, Panda A, Elankumaran S, Govindarajan D, Rockemann DD, Samal SK. The hemagglutinin-neuraminidase protein of Newcastle disease virus determines tropism and virulence. Journal of virology. 2004; 78: 4176-84.
4. Zaitsev V, von Itzstein M, Groves D, Kiefel M, Takimoto T, Portner A, et al. Second sialic acid binding site in Newcastle disease virus hemagglutinin-neuraminidase: implications for fusion. Journal of Virology. 2004; 78: 3733-41.
5. Takimoto T, Taylor GL, Connaris HC, Crennell SJ, Portner A. Role of the hemagglutinin-neuraminidase protein in the mechanism of paramyxovirus-cell membrane fusion. Journal of Virology. 2002; 76: 13028-33.
6. Ji H-F, Chi B-R, He D-Y, Li C, Hu N-N, Wang K, et al. Antitumor effects of Newcastle disease virus hemagglutinin-neuraminidase used as a molecular adjuvant. Chemical Research in Chinese Universities. 2013; 29: 270-4.
7. Ni J, Schirrmacher V, Fournier P. The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: A powerful molecular adjuvant for DNA anti-tumor vaccination. Vaccine. 2010; 28: 6891-900.
8. Ni J, Galani IE, Cerwenka A, Schirrmacher V, Fournier P. Antitumor vaccination by Newcastle Disease Virus Hemagglutinin-Neuraminidase plasmid DNA application: Changes in tumor microenvironment and activation of innate anti-tumor immunity. Vaccine. 2011; 29: 1185-93.
9. Piao B-G, Li X, Sun L-L, Kan S-F, Liu L, Huang H-Y, et al. Activity of T Cells Stimulated by Hemagglutinin-neuraminidase of Newcastle Disease Virus in vivo. Chemical Research In Chinese Universites. 2011; 27: 455-60.
10. Zeng J, Fournier P, Schirrmacher V. Induction of interferon-a and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus. Virology. 2002; 297: 19-30.
11. Jarahian M, Watzl C, Fournier P, Arnold A, Djandji D, Zahedi S, et al. Activation of natural killer cells by Newcastle disease virus hemagglutinin-neuraminidase. Journal of Virology. 2009; 83: 8108-21.
12. Baradaran A, Sieo CC, Foo HL, Illias RM, Yusoff K, Rahim RA. Cloning and in silico characterization of two signal peptides from Pediococcus pentosaceus and their function for the secretion of heterologous protein in Lactococcus lactis. Biotechnology Letters. 2013; 35: 233-8.
13. Manual OT. Avian influenza. Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. 2012.
14. Richter E, Wick G. Fluoro-immuno-cytoadherence (FICA): A new method for the identification and enumeration of antigen-binding cells. Zeitschrift für Immunitätsforschung: Immunobiology. 1977; 152: 351-62.
15. Mohanty C, Das M, R Kanwar J, K Sahoo S. Receptor mediated tumor targeting: an emerging approach for cancer therapy. Current Drug Delivery. 2011; 8: 45-58.
16. Reis CA, Osorio H, Silva L, Gomes C, David L. Alterations in glycosylation as biomarkers for cancer detection. Journal of Clinical Pathology. 2010; 63: 322-9.
17. Meany DL, Chan DW. Aberrant glycosylation associated with enzymes as cancer biomarkers. Clin Proteomics. 2011; 8.
18. Varki A, Gagneux P. Multifarious roles of sialic acids in immunity. Annals of the New York Academy of Sciences. 2012; 1253: 16-36.
19. Büll C, Boltje TJ, Wassink M, de Graaf AM, van Delft FL, den Brok MH, et al. Targeting aberrant sialylation in cancer cells using a fluorinated sialic acid analog impairs adhesion, migration, and in vivo tumor growth. Molecular Cancer Therapeutics. 2013; 12: 1935-46.
20. Freire-de-Lima L. Sweet and sour: the impact of differential glycosylation in cancer cells undergoing epithelial-mesenchymal transition. Frontiers in oncology. 2014; 4.
21. Taylor-Papadimitriou J, Burchell J, Miles D, Dalziel M. MUC1 and cancer. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 1999; 1455: 301-13.
22. Sihlbom C, van Dijk Härd I, Lidell ME, Noll T, Hansson GC, Bäckström M. Localization of O-glycans in MUC1 glycoproteins using electron-capture dissociation fragmentation mass spectrometry. Glycobiology. 2009; 19: 375-81.
23. Singh R, Bandyopadhyay D. MUC1: a target molecule for cancer therapy. Cancer biology & therapy. 2007; 6: 481-6.
24. Raha A, Varma N, Yusoff K, Ross E, Foo HL. Cell surface display system for Lactococcus lactis: a novel development for oral vaccine. Applied Microbiology and Biotechnology. 2005; 68: 75-81.
25. Ghrici M, El Zowalaty M, Omar AR, Ideris A. Induction of apoptosis in MCF-7 cells by the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus Malaysian strain AF2240. Oncology reports. 2013; 30: 1035-44.